Understand the source comparison
Best Peptides for Psoriasis: Research Comparison
Thymosin Beta-4 Blocks RORγt transcription factor, reducing Th17 differentiation IL-23/IL-17 axis upstream 5–10mg SC twice weekly ~2 hours Animal models + Phase 1 human trials (wound healing) BPC-157 Modulates FGF receptors, normalizes keratinocyte differentia
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Beta-4
- Blocks RORγt transcription factor, reducing Th17 differentiation
- IL-23/IL-17 axis upstream
- 5–10mg SC twice weekly
- ~2 hours
- Animal models + Phase 1 human trials (wound healing)
- BPC-157
- Modulates FGF receptors, normalizes keratinocyte differentiation markers
- Keratinocyte proliferation regulation
- 200–500mcg SC daily
- ~4 hours
- Animal models, observational case reports
- KPV (Tripeptide)
- Direct NF-κB inhibition in nucleus
- Inflammatory transcription at gene level
- 500mcg–1mg SC daily or 1–2% topical
- <2 hours
- In vitro studies, animal models
- LL-37 (Cathelicidin)
- Antimicrobial peptide that paradoxically triggers psoriasis in susceptible individuals
- Dendritic cell activation (pathogenic role)
- Not therapeutic. Used as disease model inducer
- ~6 hours
- Human observational (endogenous)
- GHK-Cu (Copper Peptide)
- Enhances TGF-beta and collagen synthesis, reduces MMP activity
- Tissue remodeling and barrier repair
- 1–3mg topical daily
- ~1 hour
- In vitro and cosmetic dermatology studies